Viridian Therapeutics Inc. (VRDN), a biopharmaceutical company focused on serious and rare diseases, is nearing a key development that could mark a significant milestone toward its first commercial launch, pending approval. The drug candidate in focus is Veligrotug (VRDN-001), and the proposed indication is thyroid eye disease. Veligrotug, administered intravenously, is a monoclonal antibody that...
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.